Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?

Alice Mezincescu, V. J. Karthikeyan, Sunil K. Nadar*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Although the majority of patients with CVD are treated with interventional procedures, a substantial number require medical therapy in terms of both prognosis and symptomatic relief. However, commonly used agents such as β-blockers and calcium channel blockers reduce blood pressure in patients whose resting pressures are often already low. Ranolazine is a promising agent that does not have significant effects on blood pressure or heart rate. Use of this drug has been documented in various cardiovascular conditions, including ischaemic heart disease, heart failure and arrhythmias. This review article aimed to examine current evidence on the use of ranolazine in various cardiovascular conditions in order to determine whether it is a true pluripotent cardiovascular agent or, on the other hand, a “jack of all trades, master of none.”.

Original languageEnglish
Pages (from-to)e13-e23
JournalSultan Qaboos University Medical Journal
Issue number1
Publication statusPublished - Feb 2018


  • Cardiovascular agents
  • Cardiovascular diseases
  • Drug therapy
  • Ischemic heart disease
  • Ranolazine

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?'. Together they form a unique fingerprint.

Cite this